Boston Scien Cp receives Investment Bank Analyst Rating Update
By Davit KirakosyanInvesting.com -- Here is your Pro Recap of the most head-turning deal dispatches you may have missed this week: disappointment at SiriusPoint, positive news for...
Revenue is expected to grow 9.90% this year and another 8.00% next year. Earnings are estimated to increase by 11.40% this year, and an additional 13.30% next year.
Watch our week ahead video preview, read our pick of the top stories to look out for this week (26-30 October), and view our key company earnings schedule. Michael looks at a busy...
The Boston Scientific (NYSE:BSX) share price has risen by 9.94% over the past month and it’s currently trading at 41.48. For investors considering whether to buy, hold or...
Boston Scientific Corporation is a developer, manufacturer, and marketer of medical devices. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy and Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions. Its Urology and Neuromodulation business develops and manufactures devices to treat various urological, neurological movement disorders and pelvic conditions. Its Cardiac Rhythm Management develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment include Interventional Cardiology and Peripheral Interventions. Its Interventional Cardiology develops and manufactures technologies for diagnosing and treating coronary artery disease and structural heart conditions. Its product offerings include 360 Clips and RESONATE, among others.
|Average||58.42 (+12.74% Upside)|
|No. of Analysts||26|
|Moving Averages||Buy||Buy||Buy||Buy||Strong Buy|
|Technical Indicators||Sell||Strong Buy||Strong Buy||Strong Sell||Strong Buy|
|Summary||Neutral||Strong Buy||Strong Buy||Neutral||Strong Buy|